Predictors of long term adverse events after scheduled endovascular coronary interventions
https://doi.org/10.15829/1728-8800-2018-4-46-52
Abstract
Aim. To evaluate the rate and reveal the predictors of long term adverse cardiovascular events after scheduled percutaneous coronary interventions (PCI).
Material and methods. The rate of combination endpoint (МАССЕ — Major Adverse Cardiac and Cerebrovascular Events) was assessed in 151 patient in 6 years after selective PCI by medical data analysis and phone based interview.
Results. In 6 years after scheduled PCI the mortality from cardiovascular events was in 10,6% patients, acute coronary syndrome developed in 34,4%, stroke in 6,6%. In general MACCE were noted in 40,4%. The predictors of MACCE in long term period were chronic kidney disease, contrast-induced kidney damage, baseline C-reactive protein >5,5 mg/mL. Restenoses of the previously placed stents increased the risk of MACCE 8,09 times, chronic obstructive pulmonary disease — 3,4 times, atrial fibrillation — 2,84 times, heredity by cardiovascular diseases — 2,94 times, and the very high risk of contrast-induced nephropathy (≥11 points by Mehran) — 2,15 times.
Conclusion. Assessment for the predictors of long term adverse cardiovascular events in patients after scheduled PCI makes it, based on simple clinical characteristics, to select the groups of patients with residual risk that require on-time application of more active secondary prevention strategies with further follow-up.About the Authors
E. O. Vershinina
SRI of Cardiology “Tomsk National Research Medical Center of RAS”
Russian Federation
Russian Federation
A. N. Repin
SRI of Cardiology “Tomsk National Research Medical Center of RAS”
Russian Federation
Russian Federation
References
1. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267-315. doi:10.1093/eurheartj/ehv320. Epub 2015 Aug 29.
2. Grayson AD, Moore RK, Jackson M, et al. North West Quality Improvement Programme in Cardiac Interventions. Multivariate prediction of major adverse cardiac events after 9914 percutaneous coronary interventions in the north west of England. Heart. 2006;92:658-63. doi:10.1136/hrt.2005.066415
3. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrastinduced nephropathy after percutaneous coronary intervention: development and initial validation. JACC. 2004; 44:1393-9. doi:10.1016/j.jacc.2004.06.068.
4. Vershinina EO, Repin AN, Salnikova ES. Loading dose statin therapy in elective endovascular interventions on the coronary arteries. Serdce: zhurnal dlya praktikuyushchih vrachej. 2016;15(3):181-91. (In Russ.) doi:10.18087/rhj.2016.3.2181.
5. Rapsomaniki E, Shah A, Perel P, et al. Prognostic models for stable coronary artery disease based on electronic health record cohort of 102 023 patients. Eur Heart J. 2014;35:844-52. doi:10.1093/eurheartj/eht533. Epub 2013 Dec 17.
6. Vershininа EO, Repin AN, Ryabova TR. The impact of multifocal atherosclerosis on the early and late outcomes of elective endovascular treatment of ischemic heart disease. The Siberian Medical Journal (Tomsk). 2014;29(3):87-93. (In Russ.)
7. Amarenco P, Lavallee PC, Labreuche J, et al. Coronary artery disease and risk of major vascular events after cerebral infarction. Stroke. 2013;44:1505-11. doi:10.1161/ STROKEAHA.111.000142.
8. Wauters E, Carruthers KF, Buysschaert I, et al. Influence of 23 coronary artery disease variants on recurrent myocardial infarction or cardiac death: The GRACE Genetics Study. Eur Heart J. 2013;34:993-1001. doi:10.1093/eurheartj/ehs389. Epub 2012 Nov 15.
9. Nakatani D, Sakata Y, Suna S, et al. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. Circ J. 2013;77:439-46. doi:10.1253/circj.CJ-11-1059.
10. Raber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation. 2011;123:2819-28. doi:10.1161/ CIRCULATIONAHA.110.004762. Epub 2011 Jun 6.
11. Otsuka F, Byrne RA, Yahagi K, et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J. 2015;36:2147-59. doi:10.1093/eurheartj/ehv205. Epub 2015 May 20.
12. Palhais N, Arroyo D, Lehmann S, et al. Ten-year clinical follow-up after sirolimus-eluting stent implantation. Am Heart J. 2014;167:893-9. doi:10.1016/j.ahj.2013.12.013.
13. Yamaji K, Raber L, Zanchin T, et al. Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial. Eur Heart J. 2016;37:3386-95. doi:10.1093/eurheartj/ehw343. Epub 2016 Aug 30.
14. Hu WS, Lee JH, Tsai MK, et al. А novel cardiovascular death prediction model for Chinese individuals: A prospective cohort study of 381,963 study participants. Atherosclerosis. 2017;264:19-28. doi:10.1016/j.atherosclerosis.2017.07.016. Epub 2017 Jul 14.
15. Vershininа EO, Repin AN. Acute periprocedural kidney injury in elective percutaneous coronary interventions. Eurasian Heart J. 2017;3:114. (In Russ.)
Review
For citations:
Vershinina E.O., Repin A.N. Predictors of long term adverse events after scheduled endovascular coronary interventions. Cardiovascular Therapy and Prevention. 2018;17(4):46-52. (In Russ.) https://doi.org/10.15829/1728-8800-2018-4-46-52
Views:
669
Email this article 
